Your browser doesn't support javascript.
loading
Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes.
Brunton, Nichole E; Wysokinski, Waldemar E; Hodge, David O; Vlazny, Danielle T; Houghton, Damon E; Casanegra, Ana I.
Afiliação
  • Brunton NE; Department of Internal Medicine Danbury Hospital Danbury CT USA.
  • Wysokinski WE; Department of Cardiovascular Medicine Division of Vascular Medicine Gonda Vascular Center Mayo Clinic Rochester MN USA.
  • Hodge DO; Department of Health Sciences Research Mayo Clinic Jacksonville FL USA.
  • Vlazny DT; Department of Cardiovascular Medicine Division of Vascular Medicine Gonda Vascular Center Mayo Clinic Rochester MN USA.
  • Houghton DE; Department of Cardiovascular Medicine Division of Vascular Medicine Gonda Vascular Center Mayo Clinic Rochester MN USA.
  • Casanegra AI; Department of Cardiovascular Medicine Division of Vascular Medicine Gonda Vascular Center Mayo Clinic Rochester MN USA.
Res Pract Thromb Haemost ; 5(4): e12500, 2021 May.
Article em En | MEDLINE | ID: mdl-34027287
OBJECTIVE: We assessed the number of cases with delayed anticoagulation initiation, explored the reasons for the delay, and its impact on outcome in patients with acute venous thromboembolism (VTE) treated in an organized setting of treatment initiation and continuous, prospective follow-up. METHODS: Patients with anticoagulation initiation delay >24 hours were identified within the cohort of patients with acute VTE enrolled in the Mayo Clinic Venous Thromboembolism Registry between 2013 and 2020. The reasons for treatment delay were explored by reviewing the electronic database. VTE recurrence, all-cause mortality, major bleeding, and clinically relevant nonmajor bleeding (CRNMB) were compared to those with no anticoagulation delay. RESULTS: Of 2378 patients with acute VTE, 100 (4.2%) experienced an anticoagulation delay. We identified seven reasons for treatment delays: deferring anticoagulation initiation to specialists (n = 38), thrombocytopenia (n = 10), planned or recent procedure (n = 16), active or recent bleeding (n = 12), missed diagnosis (n = 7), logistics (n = 6), and patient decision (n = 4). In seven cases, no reason was identified. We identified modifiable reasons for anticoagulation delay in 55%. At 90-day follow-up, patients with anticoagulation delay had a higher rate of mortality and major bleeding. VTE recurrence and CRNMB were not statistically different compared to those without anticoagulation delay. After adjustment for age, weight, and cancer, hazard ratios (HRs) for VTE recurrence and major bleeding remained elevated but not to a statistically significant level. CONCLUSION: In the setting of a highly organized system of anticoagulation initiation, the incidence of treatment delay is low. Yet most delays could be avoided. A low number of cases provide insufficient power to evaluate the clinical consequences of anticoagulation initiation delay; however, elevated HR for VTE recurrence and major bleeding suggest association and need for further investigation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Res Pract Thromb Haemost Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Res Pract Thromb Haemost Ano de publicação: 2021 Tipo de documento: Article